Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The incidence of breast cancer in Chinese women has increased year by year, and luminal A breast cancer commonly occurs in early-stage and postmenopausal women. This type of breast cancer is not sensitive to chemotherapy, although it has a low mortality rate and distant metastasis rate. Studies have shown that luminal A breast cancer is sensitive to endocrine therapy. Patients with breast cancer who undergo excision should be followed up and their prognosis should be monitored regularly. At present, imaging detection is mainly used in the conventional follow-up of breast cancer, but the cost of many imaging examinations is high, so a cost-effective examination is urgently needed. Recent studies have found that circulating tumor cells can be used as a new type of tumor molecular marker, which can be used to diagnose tumors, judge the prognosis and monitor the efficacy by detecting the number and characteristic protein expression of circulating tumor cells. Because circulating tumor cells may develop abnormalities 4-6 months earlier than conventional imaging examination, as long as circulating tumor cells of patients are abnormal, timely PET-CT examination will neither miss diagnosis nor delay the condition. Simultaneously, the cost of hospitalization can be obviously reduced. This non-inferiority randomized controlled clinical trial is designed to compare the differences in postoperative conditions between circulating tumor cell detection and conventional imaging examination in patients with luminal A breast cancer without lymph node metastasis.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Receptor estrogenowy dodatni (≥10%), receptor progesteronowy dodatni (≥10%) i receptor wzrostu epidermalnego (HER2) ujemny
- •Wskaźnik proliferacji Ki-67 poniżej 20%
- •Brak przerzutów do węzłów chłonnych
- •Leczenie systemowe (chemioterapia, radioterapia i hormonoterapia) zgodnie ze standardowymi wytycznymi
- •Świadoma zgoda pacjenta i jego rodziny na uczestnictwo w badaniu
✗ Disqualifies
- •Rak piersi w obu piersiach
- •Rak zapalny piersi
- •Ciąża lub karmienie piersią
- •Historia innych nowotworów lub wcześniejsza radioterapia klatki piersiowej
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 60 Years
- Last updated (source)
- May 5, 2022
- Sex
- Female only
Therapies / drugs in trial
Locations (2)
Shengjing Hospital of China Medical University
Shenyang, China
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
Shenyang, China
Trial contact
Jianyi Li
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.